• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Dow Surges Over 100 Points; EyePoint Pharmaceuticals Shares Plunge

    5/6/24 3:04:00 PM ET
    $EYPT
    $GLYC
    $LYRA
    $PRFT
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EYPT alert in real time by email

    U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 100 points on Monday.

    The Dow traded up 0.35% to 38,811.58 while the NASDAQ rose 0.95% to 16,309.74. The S&P 500 also rose, gaining, 0.82% to 5,169.93.

    Leading and Lagging Sectors

    Energy shares rose by 1.5% on Monday.

    In trading on Friday, consumer staples shares fell by 0.4%.

    Top Headline

    Shares of Spirit Airlines, Inc. (NYSE:SAVE) fell sharply during Monday’s session after reporting first-quarter results.

    Spirit Airlines reported a first-quarter fiscal 2024 revenue decline of 6.2% Y/Y to $1.265 billion, marginally missing the consensus of $1.269 billion. Adjusted EPS loss was $(1.46), down from $(0.82), missing the consensus of $(1.45).

    Equities Trading UP
                           

    • Perficient, Inc. (NASDAQ:PRFT) shares shot up 53% to $73.38 after the company disclosed an acquisition deal and first-quarter FY24 results.
    • Shares of Strong Global Entertainment, Inc. (NYSE:SGE) got a boost, surging 120% to $2.51  after FG Acquisition Corp. announced the proposed acquisition of Strong/MDI Screen Systems and the launch of Saltire Holdings.
    • XBP Europe Holdings, Inc. (NASDAQ:XBP) shares were also up, gaining 55% to $3.2680. XBP Europe Holdings was recently awarded a $40 million multi-year contract for a nationwide transformation project for His Majesty’s Passport Office.

    Equities Trading DOWN

    • Lyra Therapeutics, Inc (NASDAQ:LYRA) shares dropped 87% to $3.2680 after the company announced the ENLIGHTEN 1 trial did not meet its primary endpoint.
    • Shares of GlycoMimetics, Inc (NASDAQ:GLYC) were down 82% to $0.3330 after the company announced topline results from its Phase 3 global pivotal study of uproleselan in relapsed/refractory acute myeloid leukemia (R/R AML).
    • EyePoint Pharmaceuticals, Inc (NASDAQ:EYPT) was down, falling 42% to $11.38 after the company’s Phase 2 PAVIA trial of DURAVYU did not meet its pre-specified primary endpoint.

    Also Check This Out: Netflix, Home Depot And More On CNBC’s ‘Final Trades’

    Commodities

    In commodity news, oil traded up 0.6% to $78.56 while gold traded up 1.1% at $2,333.60.

    Silver traded up 3.6% to $27.66 on Monday, while copper rose 1.1% to $4.6085.

    Euro zone

    European shares were higher today. The eurozone's STOXX 600 rose 0.53%, Germany's DAX rose 0.96% and France's CAC 40 gained 0.49%. Spain's IBEX 35 Index rose 0.58%, while London's FTSE 100 rose 0.51%.

    Asia Pacific Markets

    Asian markets closed mixed on Monday, with Japan's Nikkei falling 0.1%, Hong Kong's Hang Seng Index jumping 0.55% and India's S&P BSE Sensex rising 0.02%.

    Economics

    No major economic reports will be released today.

    Now Read This: How To Earn $500 A Month From FMC Stock Ahead Of Q1 Earnings

    Get the next $EYPT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EYPT
    $GLYC
    $LYRA
    $PRFT

    CompanyDatePrice TargetRatingAnalyst
    EyePoint Inc.
    $EYPT
    6/17/2025$28.00Outperform
    RBC Capital Mkts
    GlycoMimetics Inc.
    $GLYC
    3/21/2025Overweight
    Cantor Fitzgerald
    EyePoint Inc.
    $EYPT
    1/7/2025$33.00Buy
    Citigroup
    EyePoint Inc.
    $EYPT
    10/16/2024Sector Outperform
    Scotiabank
    EyePoint Inc.
    $EYPT
    8/28/2024$15.00Buy
    Jefferies
    GlycoMimetics Inc.
    $GLYC
    7/26/2024Buy → Hold
    TD Cowen
    Spirit Airlines Inc.
    $SAVE
    7/17/2024$3.00 → $2.00Hold → Sell
    TD Cowen
    Spirit Airlines Inc.
    $SAVE
    7/8/2024$3.00 → $2.00Hold → Sell
    Deutsche Bank
    More analyst ratings

    $EYPT
    $GLYC
    $LYRA
    $PRFT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RBC Capital Mkts initiated coverage on EyePoint Pharmaceuticals with a new price target

    RBC Capital Mkts initiated coverage of EyePoint Pharmaceuticals with a rating of Outperform and set a new price target of $28.00

    6/17/25 7:49:38 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Cantor Fitzgerald initiated coverage on GlycoMimetics

    Cantor Fitzgerald initiated coverage of GlycoMimetics with a rating of Overweight

    3/21/25 8:14:54 AM ET
    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citigroup initiated coverage on EyePoint Pharmaceuticals with a new price target

    Citigroup initiated coverage of EyePoint Pharmaceuticals with a rating of Buy and set a new price target of $33.00

    1/7/25 7:52:05 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $EYPT
    $GLYC
    $LYRA
    $PRFT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Cavalier Jason sold $2,587 worth of shares (769 units at $3.36), decreasing direct ownership by 0.15% to 518,547 units (SEC Form 4)

    4 - Lyra Therapeutics, Inc. (0001327273) (Issuer)

    1/8/26 4:30:20 PM ET
    $LYRA
    Medical/Dental Instruments
    Health Care

    President & CEO Palasis Maria sold $5,726 worth of shares (1,702 units at $3.36), decreasing direct ownership by 0.15% to 1,096,733 units (SEC Form 4)

    4 - Lyra Therapeutics, Inc. (0001327273) (Issuer)

    1/8/26 4:30:11 PM ET
    $LYRA
    Medical/Dental Instruments
    Health Care

    Director Lurker Nancy converted options into 75,133 shares, increasing direct ownership by 34% to 294,346 units (SEC Form 4)

    4 - EyePoint, Inc. (0001314102) (Issuer)

    1/7/26 4:13:32 PM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $EYPT
    $GLYC
    $LYRA
    $PRFT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    XBP Global Launches "Enabling the Next Era of Hyper‑Automation," Redefining Intelligent Execution with Agentic AI

    IRVING, Texas, Feb. 12, 2026 (GLOBE NEWSWIRE) -- XBP Global Holdings, Inc. ("XBP Global" or "the Company") (NASDAQ:XBP), a workflow automation leader that leverages decades of industry experience, a global footprint, and agentic AI to rethink business process automation and digital transformation, announced the launch of Enabling the Next Era of Hyper‑Automation, a company‑wide campaign that reflects its vision to redesign how work is executed by embedding intelligence, autonomy, and human judgment directly into enterprise workflows. As organizations face growing complexity, fragmented systems, and increasing pressure to deliver outcomes at speed, traditional approaches to automation are

    2/12/26 8:00:00 AM ET
    $XBP
    EDP Services
    Technology

    XBP Global Named to Newsweek's America's Greatest Workplaces for Culture, Belonging & Community 2026

    IRVING, Texas, Feb. 09, 2026 (GLOBE NEWSWIRE) -- XBP Global Holdings, Inc. ("XBP Global" or "the Company") (NASDAQ:XBP), a workflow automation leader that leverages decades of industry experience, a global footprint, and agentic AI to rethink business process automation and digital transformation, today announced that it has been recognized as one of Newsweek's America's Greatest Workplaces for Culture, Belonging & Community 2026, in partnership with Plant-A Insights Group. This recognition highlights XBP Global's commitment to fostering an inclusive workplace culture where employees feel valued, heard, and connected, and where a strong sense of belonging and community underpins how teams

    2/9/26 8:00:00 AM ET
    $XBP
    EDP Services
    Technology

    EyePoint to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

    WATERTOWN, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that George O. Elston, Executive Vice President and Chief Financial Officer of EyePoint, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026 at 11:00 am ET. A webcast and subsequent archived replay of the fireside chat may be accessed via the Investors section of the Company website at www.eyepoint.bio. About EyePoint EyePoint, Inc. (NASDAQ:EYPT) is a clinical-stage biopharmaceutic

    2/5/26 7:00:00 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $EYPT
    $GLYC
    $LYRA
    $PRFT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Klein Randal T bought $80,325 worth of shares (150,000 units at $0.54) (SEC Form 4)

    4 - XBP Global Holdings, Inc. (0001839530) (Issuer)

    8/19/25 8:23:45 AM ET
    $XBP
    EDP Services
    Technology

    Director Zaderej Karen L. bought $59,000 worth of shares (10,000 units at $5.90), increasing direct ownership by 38% to 36,500 units (SEC Form 4)

    4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)

    5/19/25 4:06:14 PM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Zaderej Karen L. bought $54,450 worth of shares (10,000 units at $5.45), increasing direct ownership by 61% to 26,500 units (SEC Form 4)

    4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)

    5/15/25 4:06:14 PM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $EYPT
    $GLYC
    $LYRA
    $PRFT
    SEC Filings

    View All

    SEC Form 8-K filed by Lyra Therapeutics Inc.

    8-K - Lyra Therapeutics, Inc. (0001327273) (Filer)

    2/6/26 4:12:23 PM ET
    $LYRA
    Medical/Dental Instruments
    Health Care

    Lyra Therapeutics Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities

    8-K - Lyra Therapeutics, Inc. (0001327273) (Filer)

    1/12/26 7:30:26 AM ET
    $LYRA
    Medical/Dental Instruments
    Health Care

    EyePoint Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - EyePoint, Inc. (0001314102) (Filer)

    1/7/26 7:05:26 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $EYPT
    $GLYC
    $LYRA
    $PRFT
    Leadership Updates

    Live Leadership Updates

    View All

    XBP Global Appoints Mike Shufeldt as Chief Revenue Officer to Accelerate Growth of XBP Americas

    IRVING, Texas, Jan. 28, 2026 (GLOBE NEWSWIRE) -- XBP Global Holdings, Inc. ("XBP Global" or "the Company") (NASDAQ:XBP), a workflow automation leader that leverages decades of industry experience, a global footprint, and agentic AI to rethink business process automation and digital transformation, announced the appointment of Mike Shufeldt as Chief Revenue Officer (CRO), XBP Americas. In this role, Mr. Shufeldt will lead the revenue strategy and commercial execution, supporting the company's strategic shift toward accelerated, scalable, and client-centric growth in the Americas. The appointment highlights XBP Global's focus on strengthening its go-to-market model, driving solution-led sel

    1/28/26 8:00:00 AM ET
    $XBP
    EDP Services
    Technology

    11th Annual Palisades Turkey Trot Powered by XBP Global Returns Thanksgiving Morning with New 5K and 10K Course

    IRVING, Texas, Nov. 25, 2025 (GLOBE NEWSWIRE) -- XBP Global Holdings, Inc. ("XBP Global" or "the Company") (NASDAQ:XBP), a workflow automation leader that leverages decades of industry experience, global footprint, and agentic AI to rethink business process automation and digital transformation, returns to Pacific Palisades on Thanksgiving Day, Thursday, November 27, 2025, continuing the holiday tradition for the 11th Annual Palisades Turkey Trot. This year's race introduces a brand-new 5K and 10K course starting and finishing at Palisades Green, bringing an uplifting twist to the beloved community event. This year's run proudly supports the rebuilding of the YMCA for the Palisades-Malibu

    11/25/25 1:28:40 PM ET
    $XBP
    EDP Services
    Technology

    XBP Global Holdings, Inc. Reports Second Quarter 2025 Results

    Second Quarter 2025 Highlights XBP Europe Holdings, Inc. ("XBP Europe") completed the acquisition of Exela Technologies BPA, LLC ("BPA") and changed its name to XBP Global Holdings, Inc.      Revenue of $39.6 million, an increase of 17.8% year-over-year and 5.2% sequentiallyGross margin of 29.8%, a 1,020 bps increase year-over-year and 30 bps decrease sequentially Adjusted EBITDA of $3.3 million, an increase of 173.8% year-over-year and decrease of 11.2% sequentially IRVING, Texas and LONDON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- XBP Global Holdings, Inc. ("XBP Global" or "the Company") (NASDAQ:XBP), a multinational leader in business process automation and integration of bills, payments, an

    8/14/25 9:03:03 AM ET
    $XBP
    EDP Services
    Technology

    $EYPT
    $GLYC
    $LYRA
    $PRFT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Lyra Therapeutics Inc.

    SC 13D/A - Lyra Therapeutics, Inc. (0001327273) (Subject)

    12/16/24 9:02:59 PM ET
    $LYRA
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Spirit Airlines Inc.

    SC 13G - Spirit Airlines, Inc. (0001498710) (Subject)

    12/6/24 9:37:58 AM ET
    $SAVE
    Air Freight/Delivery Services
    Consumer Discretionary

    SEC Form SC 13G filed by GlycoMimetics Inc.

    SC 13G - GLYCOMIMETICS INC (0001253689) (Subject)

    11/27/24 2:22:44 PM ET
    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EYPT
    $GLYC
    $LYRA
    $PRFT
    Financials

    Live finance-specific insights

    View All

    XBP Global Holdings, Inc. Reports Third Quarter 2025 Results

    Third Quarter 2025 Highlights XBP Europe Holdings, Inc. ("XBP Europe") finalized the acquisition of Exela Technologies BPA, LLC ("Exela BPA") and changed its name to XBP Global Holdings, Inc. on July 29, 2025XBP Europe issued approximately 81.8 million shares for an equity valuation of the combined company of $585.7 million, or $4.98/share    Reported revenue1 totaled $209.1 million, a decline of 10.4% year-over-yearCombined Pro Forma Revenue2 totaled $220.4 million, a decline of 18.1% year-over-yearGross margin on a reported basis was 22.0%, a 310 basis point increase year-over-yearPro Forma Gross Margin2 of 21.9%, a 190 basis point increase year-over-yearPro Forma Adjusted EBITDA2,3 of $2

    11/14/25 4:01:00 PM ET
    $XBP
    EDP Services
    Technology

    XBP Global Schedules Conference Call for Third Quarter 2025 Financial Results

    IRVING, Texas, Nov. 10, 2025 (GLOBE NEWSWIRE) -- XBP Global Holdings, Inc. ("XBP Global" or "the Company") (NASDAQ:XBP), a workflow automation leader that leverages decades of industry experience, global footprint and agentic AI to rethink business process automation and digital transformation, announced today that it will host a live conference call with the financial community on November 14, 2025 at 4:30 pm Eastern Time to discuss its third quarter 2025 financial results, accompanied by a live webcast. The press release announcing third quarter 2025 results will be issued after market close on November 14, 2025. Hosting the call will be Andrej Jonovic, Chief Executive Officer, and Deja

    11/10/25 8:00:00 AM ET
    $XBP
    EDP Services
    Technology

    EyePoint to Report Third Quarter 2025 Financial Results on November 5, 2025

    WATERTOWN, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, November 5, 2025 to report its third quarter 2025 financial results and highlight recent corporate developments. To access the live conference call, please register using the audio conference link: https://edge.media-server.com/mmc/p/fgkir3sg. A live audio webcast of the event can be accessed via the Investors section of the Company website at www.eyepointpharm

    10/29/25 7:00:00 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $EYPT
    $GLYC
    $LYRA
    $PRFT
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    What Does the Recent Purchase at GlycoMimetics Inc. on Jun 20 Indicate?

    Recently, on June 20, 2024, an insider purchase was made at GlycoMimetics Inc., grabbing the attention of investors. According to the SEC Form 4 filing, SVP Finance, CFO Hahn Brian M. bought $4,335 worth of shares (17,500 units at $0.25), boosting direct ownership by 33% to 70,643 units. Insider transactions are closely monitored by investors as they can provide insights into the company's prospects and the confidence of insiders in the business. Let's delve deeper into the recent insider purchase and analyze any potential patterns or significance in comparison to other insider transactions at GlycoMimetics Inc. In early April 2024, Goldberg Mark Alan was granted 4,584 shares, augmenting di

    6/20/24 6:20:00 PM ET
    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care